RAD51 and neoplasm: Of note, an exploratory analysis showed that patients with homologous recombination deficient (HRD) tumours, as determined by a RAD51 foci formation assay, had prolonged mPFS as compared to patients with proficient tumours (11.2 vs. 5.4 months) [91].